Abstract
Background Tumour-promoting inflammation is a “hallmark” of cancer and conventional epidemiological studies have reported links between various inflammatory markers and cancer risk. The causal nature of these relationships and, thus, the suitability of these markers as intervention targets for cancer prevention is unclear.
Methods We meta-analysed 6 genome-wide association studies of circulating inflammatory markers comprising 59,969 participants of European ancestry. We then used combined cis-Mendelian randomization and colocalisation analysis to evaluate the causal role of 66 circulating inflammatory markers in risk of 30 adult cancers in 338,162 cancer cases and up to 824,556 controls. Genetic instruments for inflammatory markers were constructed using genome-wide significant (P < 5.0 x 10-8) cis-acting SNPs (i.e. in or ±250 kb from the gene encoding the relevant protein) in weak linkage disequilibrium (LD, r2 < 0.10). Effect estimates were generated using inverse-variance weighted random-effects models and standard errors were inflated to account for weak LD between variants with reference to the 1000 Genomes Phase 3 CEU panel. A false discovery rate (FDR)-corrected P-value (“q-value”) < 0.05 was used as a threshold to define “strong evidence” to support associations and 0.05 ≤ q-value < 0.20 to define “suggestive evidence”. A colocalisation posterior probability (PPH4) > 70% was employed to indicate support for shared causal variants across inflammatory markers and cancer outcomes.
Results We found strong evidence to support an association of genetically-proxied circulating pro-adrenomedullin concentrations with increased breast cancer risk (OR 1.19, 95% CI 1.10-1.29, q-value=0.033, PPH4=84.3%) and suggestive evidence to support associations of interleukin-23 receptor concentrations with increased pancreatic cancer risk (OR 1.42, 95% CI 1.20-1.69, q-value=0.055, PPH4=73.9%), prothrombin concentrations with decreased basal cell carcinoma risk (OR 0.66, 95% CI 0.53-0.81, q-value=0.067, PPH4=81.8%), macrophage migration inhibitory factor concentrations with increased bladder cancer risk (OR 1.14, 95% CI 1.05-1.23, q-value=0.072, PPH4=76.1%), and interleukin-1 receptor-like 1 concentrations with decreased triple-negative breast cancer risk (OR 0.92, 95% CI 0.88-0.97, q-value=0.15), PPH4=85.6%). For 22 of 30 cancer outcomes examined, there was little evidence (q-value ≥ 0.20) that any of the 66 circulating inflammatory markers examined were associated with cancer risk.
Conclusion Our comprehensive joint Mendelian randomization and colocalisation analysis of the role of circulating inflammatory markers in cancer risk identified potential roles for 5 circulating inflammatory markers in risk of 5 site-specific cancers. Contrary to reports from some prior conventional epidemiological studies, we found little evidence of association of circulating inflammatory markers with the majority of site-specific cancers evaluated.
Competing Interest Statement
DG is employed part-time by Novo Nordisk, unrelated to the submitted work. Where authors are identified as personnel of the International Agency for Research on Cancer / World Health Organization, the authors alone are responsible for the views expressed in this article and they do not necessarily represent the decisions, policy or views of the International Agency for Research on Cancer / World Health Organization.
Funding Statement
JY is supported by a Cancer Research UK Population Research Postdoctoral Fellowship (C68933/A28534). SJL, KKT and RMM are supported by Cancer Research UK (C18281/A29019) programme grant (the Integrative Cancer Epidemiology Programme) (https://www.cancerresearchuk.org/). KKT is also supported by Cancer Research UK (PPRCPJT\100005) and World Cancer Research Fund (IIG_FULL_2020_022) grants. RMM is a National Institute for Health Research Senior Investigator (NIHR202411). RMM is also supported by the NIHR Bristol Biomedical Research Centre which is funded by the NIHR (BRC-1215-20011) and is a partnership between University Hospitals Bristol and Weston NHS Foundation Trust and the University of Bristol. Department of Health and Social Care disclaimer: The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. JWR, KB, and GDS are part of the Medical Research Council Integrative Epidemiology Unit at the University of Bristol which is supported by the Medical Research Council (MC_UU_00011/1, MC_UU_00011/3, MC_UU_00011/6, and MC_UU_00011/4) and the University of Bristol (https://mrc.ukri.org/; https://www.bristol.ac.uk/). VK is funded by Academy of Finland Project 326291 and the European Unions Horizon 2020 grant agreement no. 848158 (EarlyCause). NM is supported by the French National Cancer Institute (INCa SHSESP20, grant No. 2020-076). SSZ is supported by a National Institute for Health Research Clinical Lectureship and works in centres supported by Versus Arthritis (grant no. 21173, 21754 and 21755). INTEGRAL-ILCCO is supported by a National Institutes of Health grant (U19 CA203654) (https://www.nih.gov/). The International Lung Cancer Consortium is supported by a National Cancer Institute grant (U19CA203654) (https://www.cancer.gov/).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
We obtained summary genetic association data on breast cancer risk from the Breast Cancer Association Consortium (https://bcac.ccge.medschl.cam.ac.uk/), ovarian cancer risk from the Ovarian Cancer Association Consortium (https://ocac.ccge.medschl.cam.ac.uk/), endometrial cancer risk from the Endometrial Cancer Association Consortium (https://www.ebi.ac.uk/gwas/publications/30093612#study_panel), non-Hodgkin lymphoma risk from Burrows et al. (10.5523/bris.aed0u12w0ede20olb0m77p4b9), and basal cell carcinoma risk from Adolphe et al (https://www.ebi.ac.uk/gwas/publications/33549134#study_panel). Approval was received to use restricted summary genetic association data from GECCO, INTEGRAL ILCCO, and PRACTICAL consortia after submitting a proposal to access this data. Summary genetic association data from these consortia can be accessed by contacting GECCO (kafdem{at}fredhutch.org, INTEGRAL ILCCO (rayjean.hung{at}lunenfeld.ca) (https://ilcco.iarc.fr/), and PRACTICAL (practical{at}icr.ac.uk). Approval was also received to use restricted summary genetic association data on pancreatic cancer risk via dbGaP release phs000206.v5.p3. To enquire about gaining access to summary genetic association data for renal and head and neck cancer risk, contact brennanp{at}iarc.fr. To enquire about gaining access to summary genetic association data for bladder cancer risk, contact bart.kiemeney{at}radboudumc.nl.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Members of the Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome (PRACTICAL) consortium are provided in Supplementary Note. Further information on the PRACTICAL consortium can be found at http://practical.icr.ac.uk/. Members of the International Lung Cancer Consortium are provided in the Acknowledgements.
Data Availability
Summary genetic association data from GWAS meta-analyses will be made publicly available upon acceptance of this manuscript for publication.
